Nurix Therapeutics swings to Q3 profit on Roche deal proceeds

what happened

Newsmetry API reported that Nurix Therapeutics’ third-quarter revenue reached $673.06 million, driven mainly by license revenue from Roche and a milestone payment from Sanofi. The biopharmaceutical company swung to a quarterly profit.

Net income was $549.81 million, while diluted earnings per share came to $4.73. Operating income totaled $559.45 million, pretax profit was $563.41 million and operating expenses were $113.61 million. Lower research and development costs reflected cost sharing with Roche. General and administrative expenses increased because of consulting and business-development spending tied to the Roche transaction.

Nurix ended the quarter with $1.1 billion in cash and expects its funding runway to extend into the second half of 2029. The company plans to broaden bexobrutideg development into immune-mediated diseases, including CSU and MS, and to enroll about 30 patients for each tumor type in NX-1607 expansion cohorts. The average analyst rating is “buy,” with 13 “strong buy” or “buy” recommendations, one “hold” and no “sell” or “strong sell” calls. The median 12-month price target is $34.00, compared with a $22.35 closing price on October 9.

why it matters

The quarter shows how strongly Nurix’s reported results were influenced by partner-related license and milestone payments. Its cash balance and planned clinical expansion are the main indicators for assessing the company’s operating runway and development plans. Analyst ratings and the stated target reflect current market assessments, not a price forecast.

instruments